The Moat Index

Avalo Therapeutics, Inc.

AVTX · Healthcare · $358.6M mkt cap · FY2025 filings · Shallow moat ·

Doesn't clear the bar

43/ 100
Shallow moat

The four filters

Pricing power70

Median gross margin 88.2% over 8y, variable.

Returns on capital7

Median ROIC -85.7%, above the 9% hurdle in 20% of years.

Balance-sheet safety55

Net cash position — no leverage risk.

Capital discipline44

Owner earnings trend unclear, share count n/a.

Margin of safety

Above valueOn sale
No price data
Owner earnings (normalized)
Est. intrinsic value / share
Recent price
$19.37
Discount to value
No price data

Conservative model: 9% discount rate, 0% assumed growth (capped at 4%), maintenance capex ≈ min(capex, D&A).

14 years of fundamentals

The business, in plain English

It earned −85.7% on invested capital in FY2025, with a median of −85.7% across 5 filed years. The Returns on Capital filter above scores it 7/100.

The balance sheet carried $0 of total debt in FY2017. Balance-Sheet Safety scores it 55/100.

The share count rose 2749.3% between FY2014 and FY2025 — existing owners have been diluted over the record. Capital Discipline scores it 44/100.

Put together: Pricing Power is the strongest of the four filters (70/100) and Returns on Capital the weakest (7/100), which is how AVTX lands at 43/100 — a Shallow moat.

This breakdown is generated from the filed numbers and sub-scores above — no outside narrative, no estimates. Where a filing doesn’t disclose an input, the sentence that would need it is omitted instead of guessed.

FY2012–FY2025 · 14 fiscal years, normalized from AVTX’s SEC filings

RevenueSales, as filed$59000 FY2025
$0$20M2012201720222025
Gross marginRevenue kept after cost of goods33.3% FY2023
0%50%100%2012201720222025
Return on invested capitalOperating profit on the capital employed−85.7% FY2025
−1000%−500%0%2012201720222025
Owner earningsCash an owner could take out−$78.3M FY2025
−$50M$02012201720222025

Gaps in a line mean that item isn’t in AVTX’s filings for that year — the series is never interpolated or estimated. The Table view lists every filed value, including operating and net margins, total debt, and share count.

Moat Score history

3 logged readings since Jul 17, 2026 · append-only, never rewritten

Moat Score over timeLast scored reading of each day, on the 0–100 scale42.9 / 100
0406080100WideNarrowShallowNo moatJul 17, 2026

Score history begins Jul 17, 2026 — the record builds from here and can’t be backfilled.

Tier changesSame-methodology crossings of the Wide / Narrow / Shallow bars

None yet — AVTX has read Shallow moat for every logged capture since Jul 17, 2026.

Scores are logged append-only and never overwritten — this record can’t be backfilled, which is exactly why it’s worth keeping.

Healthcare context

#206 of 440 scored Healthcare companies, ranked by Moat Score.

Nearest peers by Moat Score

  1. #204NKTR NEKTAR THERAPEUTICS43.0 out of 100, Shallow moatShallow moat
  2. #205SSKN STRATA SKIN SCIENCES, INC.43.0 out of 100, Shallow moatShallow moat
  3. #207KEQU Kewaunee Scientific Corporation42.7 out of 100, Shallow moatShallow moat
  4. #208ESMC Escalon Medical Corp.42.6 out of 100, Shallow moatShallow moat

Compare AVTX with its nearest peersAll Healthcare companies on the Index →

Common questions about AVTX

Does Avalo Therapeutics, Inc. have an economic moat?
Based on its FY2025 SEC filings, the Moat Index scores Avalo Therapeutics, Inc. (AVTX) 42.9 out of 100 — a Shallow moat. The four filters behind that score (each 0–100): pricing power 70, returns on capital 7, balance-sheet safety 55, capital discipline 44.
How has AVTX's Moat Score changed over time?
The record logs 3 readings since Jul 17, 2026; the latest reads 42.9 out of 100 (shallow moat). No tier changes on record yet. The history is append-only — readings are only ever added, never rewritten.
Embed this score on your site

One iframe, no script. The badge shows AVTX’s live Moat Score, updates itself as new filings are scored, and links back here. How it works.

<iframe
  src="https://buylikebuffett.com/embed/AVTX"
  width="340" height="150" style="border:0"
  title="AVTX Moat Score — The Moat Index"
  loading="lazy"></iframe>
Avalo Therapeutics, Inc. (AVTX) Moat Score — The Moat Index · Buy Like Buffett